On Nov 02, major Wall Street analysts update their ratings for $Merck & Co (MRK.US)$, with price targets ranging from $120 to $125.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $123.
BofA Securities analyst Charlie CY Yang maintains with a buy rating, and maintains the target price at $120.
UBS analyst Colin Bristow maintains with a buy rating, and adjusts the target price from $142 to $125.
Leerink Partners analyst Joseph Schwartz maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Merck & Co (MRK.US)$'s main analysts recently are as follows:
Ongoing uncertainty surrounding Gardasil and the market in China as we approach 2024 has been highlighted following the company's third quarter report. The analyst has revised estimates subsequent to the third quarter earnings surpassing expectations and the company largely maintaining its outlook.
Merck's third-quarter results slightly surpassed expectations in terms of revenue and earnings. Despite this, the company's stock faced a bit of pressure following the adjustment of their revenue forecast and a reduction in EPS guidance, now anticipated to be between $7.72 and $7.77, primarily due to a charge associated with previous acquisitions. Looking ahead, while revenue projections for 2024 remain largely the same with a slight increase in EPS expectations, estimates for 2025 have been scaled back on account of anticipated lower Gardasil sales and heightened operational expenditures.
Merck's adjustment of expectations for Gardasil is seen as a positive development, although the introduction of new investments may still require a shift in narrative. The potential of Winrevair to catalyze this change remains uncertain.
Here are the latest investment ratings and price targets for $Merck & Co (MRK.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月2日，多家华尔街大行更新了$默沙东 (MRK.US)$的评级，目标价介于120美元至125美元。
摩根士丹利分析师Terence Flynn维持持有评级，维持目标价123美元。
美银证券分析师Charlie CY Yang维持买入评级，维持目标价120美元。
瑞士银行分析师Colin Bristow维持买入评级，并将目标价从142美元下调至125美元。
Leerink Partners分析师Joseph Schwartz维持买入评级。
此外，综合报道，$默沙东 (MRK.US)$近期主要分析师观点如下：
截至2024年，围绕宫颈癌疫苗Gardasil以及中国市场的不确定性持续存在，随着公司发布的第三季度报告，这一情况受到了强调。分析师在第三季度收入超出预期并且公司基本保持其前景之后，已修订了估算。
默沙东第三季度的业绩略高于预期，无论是营业收入还是每股收益。尽管如此，公司的股价在调整营收预测以及降低每股收益指引后略受压力，现预计在7.72至7.77美元之间，主要是因为与之前收购相关的费用。展望未来，尽管2024年的营收预测基本保持不变，并且每股收益预期略有增加，但由于预期的Gardasil销售下降和运营支出增加，2025年的估算已经被削减。
默沙东对宫颈癌疫苗的预期调整被视为积极发展，尽管引入新投资可能仍然需要改变叙述。Winrevair发挥作用引发这种变化的潜力仍然不确定。
以下为今日4位分析师对$默沙东 (MRK.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
